OUP (Osage University Partners)

Founded 2009
Founders Robert Adelson


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 154
Average round size
The average size of a deal this fund participated in
Portfolio companies 101
Rounds per year 12.83
Lead investments 4
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 37
Key employees 5
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical

In 2009 was created OUP (Osage University Partners), which is appeared as VC. The main office of represented VC is situated in the Bala Cynwyd. The fund was located in North America if to be more exact in United States.

Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. We can highlight the next thriving fund investment areas, such as Biotechnology, Artificial Intelligence. The fund has no exact preference in some founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the most popular portfolio startups of the fund, we may highlight Receptos, Cardioxyl Pharmaceuticals, Guardant Health.

This organization was formed by Robert Adelson. We also calculated 5 valuable employees in our database.

Deals in the range of 10 - 50 millions dollars are the general things for fund. The top amount of exits for fund were in 2017. The real fund results show that this VC is 16 percentage points less often commits exit comparing to other companies. The typical startup value when the investment from OUP (Osage University Partners) is 50-100 millions dollars. The fund is constantly included in 7-12 deals per year. The top activity for fund was in 2018. Despite it in 2019 the fund had an activity. Opposing the other organizations, this OUP (Osage University Partners) works on 9 percentage points less the average amount of lead investments.

The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the OUP (Osage University Partners), startups are often financed by OrbiMed, BioAdvance, Sutter Hill Ventures. The meaningful sponsors for the fund in investment in the same round are Sutter Hill Ventures, The Column Group, HBM Healthcare Investments AG. In the next rounds fund is usually obtained by General Catalyst, Lux Capital, OrbiMed.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Glyphic Biotechnologies

Life Science
$6M08 Jul 2021 San Francisco, California, United States

Hack The Box

Cyber Security
Information Technology
Penetration Testing
$10M12 Apr 2021 Folkestone and Hythe, England, United Kingdom

Fortis Therapeutics

$40M29 Mar 2021 San Diego, California, United States

Artizan Biosciences

Life Science
$11M01 Mar 2021 New York, United States

Cyteir Therapeutics

$80M11 Feb 2021 Cambridge, Massachusetts, United States

Delfi Diagnostics

Health Care
Health Diagnostics
$100M12 Jan 2021 Baltimore, Maryland, United States

Neuros Medical

Health Care
Life Science
Medical Device
$38M07 Jan 2021 Ohio, United States

Atsena Therapeutics

Health Care
$55M16 Dec 2020 Durham, North Carolina, United States

Menlo Security

Cyber Security
Network Security
$100M12 Nov 2020 Mountain View, California, United States
ReCode Therapeutics Raises Oversubscribed Series B Financing Round of $80 Million

– ReCode Therapeutics announced the closing of an $80m Series B financing round co-led by Pfizer Ventures and EcoR1 Capital.
– The round was led by Pfizer Ventures and EcoR1 Capital.
– New investors include Sanofi Ventures, funds managed by Tekla Capital Management, Superstring Capital and NS Investment.
– Existing investors who participated included OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, and Osage University Partners.

DiCE Molecules Announces $60 Million Series C-1 Financing

– DiCE Molecules, a biopharmaceutical company leveraging its proprietary DNA-encoded library platform to discover and develop next-generation therapeutics in immunology and other therapeutic areas, announced the completion of its $60 million Series C-1 financing.
– The financing was led by RA Capital Management and Sands Capital, with participation from new investors Janus Henderson Investors, Deep Track Capital and Logos Capital.
– Existing investors Northpond Ventures, Eventide Asset Management, Driehaus Capital Management, Soleus Capital, New Leaf Venture Partners, Osage University Partners and Asymmetry Capital Management also participated in the round.
– With the closing of this Series C-1 financing round, the Company has raised approximately $200 million to date.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent OUP (Osage University Partners)?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: